CRISPR gene editing tested as last hope for tough lung cancers
NCT ID NCT07461727
Summary
This early-stage study is testing a new gene-editing treatment called EDB-102 for people with advanced lung cancer that has spread to the liver and stopped responding to standard drugs. The treatment uses CRISPR technology, delivered directly to the liver, to try to disable a specific cancer-causing gene. The main goals are to see if the treatment is safe and to find the right dose for future studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.